28-Mar-2024
TipRanks (Tue, 26-Mar 8:50 AM ET)
TipRanks (Sun, 24-Mar 9:40 PM ET)
Globe Newswire (Thu, 29-Feb 7:55 AM ET)
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
Globe Newswire (Tue, 27-Feb 8:30 AM ET)
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
Globe Newswire (Thu, 15-Feb 8:30 AM ET)
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
Globe Newswire (Mon, 5-Feb 8:30 AM ET)
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Globe Newswire (Tue, 9-Jan 7:55 AM ET)
Globe Newswire (Wed, 3-Jan 8:30 AM ET)
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Vericel trades on the NASDAQ stock market under the symbol VCEL.
As of March 28, 2024, VCEL stock price declined to $52.02 with 446,713 million shares trading.
VCEL has a beta of 1.24, meaning it tends to be more sensitive to market movements. VCEL has a correlation of 0.12 to the broad based SPY ETF.
VCEL has a market cap of $2.52 billion. This is considered a Mid Cap stock.
Last quarter Vericel reported $65 million in Revenue and $.26 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.09.
In the last 3 years, VCEL stock traded as high as $68.94 and as low as $17.30.
The top ETF exchange traded funds that VCEL belongs to (by Net Assets): IJR, XBI, VTI, IWM, VXF.
VCEL has outperformed the market in the last year with a price return of +78.9% while the SPY ETF gained +33.6%. VCEL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +47.0% and +16.9%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
VCEL support price is $51.21 and resistance is $53.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCEL stock will trade within this expected range on the day.